TRCT
ORIC icon

Tower Research Capital (TRC)’s Oric Pharmaceuticals ORIC Stock Holding History

Tower Research Capital (TRC)’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Buy
8,984
+8,541
+1,928% +$97K ﹤0.01% 2084
2025
Q4 		$3.62K Sell
443
-2,915
-87% -$33.6K ﹤0.01% 4338
2025
Q3 		$40.3K Sell
3,358
-8,399
-71% -$88.4K ﹤0.01% 2708
2025
Q2 		$119K Buy
11,757
+10,913
+1,293% +$73.3K ﹤0.01% 2238
2025
Q1 		$4.71K Sell
844
-13,817
-94% -$121K ﹤0.01% 4209
2024
Q4 		$118K Buy
14,661
+13,384
+1,048% +$123K ﹤0.01% 2065
2024
Q3 		$13.1K Sell
1,277
-3,726
-74% -$36.8K ﹤0.01% 3542
2024
Q2 		$35.4K Buy
5,003
+4,253
+567% +$38.1K ﹤0.01% 3362
2024
Q1 		$10.3K Sell
750
-8,505
-92% -$101K ﹤0.01% 3713
2023
Q4 		$85.1K Buy
9,255
+1,517
+20% +$11K ﹤0.01% 2761
2023
Q3 		$46.8K Buy
7,738
+5,635
+268% +$46.2K ﹤0.01% 2600
2023
Q2 		$16.3K Buy
+2,103
New +$11.9K ﹤0.01% 3570
2023
Q1 		– Sell
-9,077
Closed -$53K – 6157
2022
Q4 		$53K Buy
9,077
+2,110
+30% +$7.12K ﹤0.01% 2304
2022
Q3 		$22K Sell
6,967
-5,126
-42% -$20.5K ﹤0.01% 3868
2022
Q2 		$55K Sell
12,093
-5,437
-31% -$21.7K ﹤0.01% 2799
2022
Q1 		$94K Buy
17,530
+16,717
+2,056% +$151K ﹤0.01% 2250
2021
Q4 		$12K Sell
813
-1,697
-68% -$26.5K ﹤0.01% 4308
2021
Q3 		$53K Buy
2,510
+647
+35% +$13.1K ﹤0.01% 2921
2021
Q2 		$32K Buy
1,863
+311
+20% +$6.82K ﹤0.01% 3428
2021
Q1 		$38K Sell
1,552
-1,083
-41% -$34.2K ﹤0.01% 3356
2020
Q4 		$89K Sell
2,635
-5,093
-66% -$146K ﹤0.01% 2461
2020
Q3 		$193K Buy
7,728
+7,290
+1,664% +$174K ﹤0.01% 2610
2020
Q2 		$15K Buy
+438
New +$14K ﹤0.01% 3820

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Tower Research Capital (TRC)'s ORIC Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Oric Pharmaceuticals (ORIC) stake by 1,928% in Q1 2026, buying an estimated $97K and bringing the position to 8,984 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

Tower Research Capital (TRC) first reported a position in ORIC in Q2 2020 and has held it in 23 quarters since. The position peaked at $193K in Q3 2020. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Tower Research Capital (TRC) held 8,984 shares of Oric Pharmaceuticals worth $114K as of Q1 2026.
  • Tower Research Capital (TRC) bought 8,541 Oric Pharmaceuticals shares in Q1 2026, an estimated $97K.
  • Oric Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2084 holding.
  • Tower Research Capital (TRC) first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Oric Pharmaceuticals position peaked at $193K in Q3 2020.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.